INTEGRATED BIOPHARMA INC reported nine months ended March 31, 2026 results: revenue $34.1 million, net income net loss of $1.5 million, EPS $(0.05).
“ended March 31, 2026 compared to operating income in the quarter ended March 31, 2025 of approximately $0.7 million. Revenue for the nine-month period ended March 31, 2026 was $34.1 million compared to $40.2 million for the nine-month period ended March 31, 2025, a decrease of $6.1 million or 15.2%. The Company had an operating loss for the nine-month period ended”
Earnings Releases
INTEGRATED BIOPHARMA INC reported quarter ended March 31, 2026 results: revenue $10.1 million, net income net loss of $0.8 million, EPS $(0.03).
“BioPharma, Inc. ((OTCQX: INBP)) (the “Company” or “INBP”) reports its financial results for the quarter ended March 31, 2026. Revenue for the quarter ended March 31, 2026 was $10.1 million compared to $13.9 million for the quarter ended March 31, 2025, a decrease of $3.8 million or 27.3%. The Company had an operating loss of $1.1 million in the quarter ended March”
Auditor Changes
Marcum LLP resigned as auditor of INTEGRATED BIOPHARMA INC.
“On April 24, 2025, Marcum resigned as the Company's independent registered public accounting firm, and CBIZ CPAs was engaged to serve as the independent registered public accounting firm of the Company for the year ending June 30, 2025, effective immediately.”
Auditor Changes
INTEGRATED BIOPHARMA INC engaged CBIZ CPAs P.C. as its auditor.
“On April 24, 2025, Marcum resigned as the Company's independent registered public accounting firm, and CBIZ CPAs was engaged to serve as the independent registered public accounting firm of the Company for the year ending June 30, 2025, effective immediately.”
Debt Financings
INTEGRATED BIOPHARMA INC incurred debt of $500,000.00 with PNC Bank, National Association at Daily one-month SOFR plus 250 basis points (2.50%) maturing April 5, 2026.
“a Convertible Equipment Line of Credit in an amount in the aggregate at any time outstanding not to exceed $500,000.00 (the "Convertible ELOC")”
Debt Financings
INTEGRATED BIOPHARMA INC incurred revolving credit of $4,000,000.00 with PNC Bank, National Association at Daily one-month SOFR plus 250 basis points (2.50%) maturing April 5, 2026.
“The Loan Agreement provides a committed revolving line of credit under which the Borrower may request and the Bank will make advances to the Borrower from time to time until April 5, 2026, (the "Expiration Date"), in an aggregate amount outstanding at any time not to exceed $4,000,000.00”
Earnings Releases
INTEGRATED BIOPHARMA INC reported quarter ended March 31, 2024 results: revenue $13.1 million, net income $0.3 million, EPS $0.01.
“(the “Company” or “INBP”) reports its financial results for the quarter ended March 31, 2024. Revenue for each of the quarters ended March 31, 2024 and 2023 were approximately $13.1 million. The Company had operating income for the quarter ended March 31, 2024 and 2023 of approximately $0.4 million and $44,000, respectively. Revenue for the nine-month period ended”
Earnings Releases
INTEGRATED BIOPHARMA INC reported the quarter ended December 31, 2023 results: revenue $11.5 million, net income net loss of approximately $0.4 million, EPS $0.01.
“Inc. ((OTCQX: INBP)) (the “Company” or “INBP”) reports its financial results for the quarter ended December 31, 2023. Revenue for the quarter ended December 31, 2023 was $11.5 million compared to $12.3 million for the quarter ended December 31, 2022, a decrease of $0.8 million or 6.5%. The Company had operating losses for the quarters ended December 31, 2023”
Shareholder Votes
INTEGRATED BIOPHARMA INC shareholders approved Ratify the appointment of Marcum LLP as the Company’s independent auditors for fiscal year ending June 30, 2024 at the 2023-11-27 meeting.
“For Against Abstain 23,762,534 7,281 -”
Shareholder Votes
INTEGRATED BIOPHARMA INC shareholders approved Non-binding, Advisory Vote on Executive Compensation at the 2023-11-27 meeting.
“For Against Abstain Broker Non-Votes 19,964,583 2,510,524 1,715 1,292,993”
Shareholder Votes
INTEGRATED BIOPHARMA INC shareholders approved Election of Class II directors for a three-year term at the 2023-11-27 meeting.
“Christina Kay 20,393,822 2,083,000 1,292,993 Robert Canarick 22,301,725 175,097 1,292,993 William H Milmoe 22,285,400 191,422 1,292,993”
Earnings Releases
INTEGRATED BIOPHARMA INC reported the quarter ended September 30, 2023 results: revenue $12.9 million, net income net loss of approximately $59,000 or $0.00 per share, EPS $0.00 per share of common stock.
“Inc. (OTCQX: INBP) (the “Company” or “INBP”) reports its financial results for the quarter ended September 30, 2023. Revenue for the quarter ended September 30, 2023 was $12.9 million compared to $12.3 million for the quarter ended September 30, 2022, an increase of $0.6 million or approximately 4.9%. The Company had an operating loss for the quarter ended”
Earnings Releases
INTEGRATED BIOPHARMA INC reported fiscal year ended June 30, 2023 results: revenue $50.7 million, net income a net loss of approximately $34,000 or $0.00 per share of common stock, EPS $0.00 per share of common stock.
“Revenues for the fiscal year ended June 30, 2023 were $50.7 million compared to $56.2 million for the fiscal year ended June 30, 2022, a decrease of $5.5 million or 9.8%.”
Earnings Releases
INTEGRATED BIOPHARMA INC reported quarter ended June 30, 2023 results: revenue $13.0 million, net income approximately $40,000 or $0.00 per share of common stock, EPS $0.00 per share of common stock.
“Revenue for the quarter ended June 30, 2023 was $13.0 million compared to $13.3 million for the quarter ended June 30, 2022, a decrease of $0.3 million or 2.3%.”
Earnings Releases
INTEGRATED BIOPHARMA INC reported financial results for the three and nine months ended March 31, 2023.
“On May 11, 2023, Integrated Biopharma, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended March 31, 2023.”
Earnings Releases
INTEGRATED BIOPHARMA INC reported the six-month period ended December 31, 2022 results: revenue $24.6 million, net income approximately $90,000, EPS $0.00 per share of common stock.
“31, 2022 of approximately $33,000 and operating income of $0.7 million for the quarter ended December 31, 2021. Revenue for the six-month period ended December 31, 2022 was $24.6 million compared to $27.3 million for the six-month period ended December 31, 2021, a decrease of $2.7 million or 9.9%. The Company had an operating loss for the six-month period ended”
Earnings Releases
INTEGRATED BIOPHARMA INC reported the quarter ended December 31, 2022 results: revenue $12.3 million, net income approximately $55,000, EPS $0.00 per share of common stock.
“Inc. ((OTCQX: INBP)) (the “Company” or “INBP”) reports its financial results for the quarter ended December 31, 2022. Revenue for the quarter ended December 31, 2022 was $12.3 million compared to $14.6 million for the quarter ended December 31, 2021, a decrease of $2.3 million or 15.6%. The Company had an operating loss for the quarter ended December 31, 2022”
Shareholder Votes
INTEGRATED BIOPHARMA INC shareholders approved Ratification of appointment of Marcum LLP as independent auditors for the fiscal year ending June 30, 2023 at the 2022-11-28 meeting.
“Proposal No. 2 – To ratify the appointment of the Company ’ s independent auditors for the fiscal year ending June 30, 2023 The Company’s stockholders voted in favor of ratifying the appointment of Marcum LLP as the Company’s independent auditors for the fiscal year ending June 30, 2023. The final voting results were as follows: For Against Abstain 23,403,076 25,801 30,000”
Shareholder Votes
INTEGRATED BIOPHARMA INC shareholders approved Election of one Class III director for a three-year term to serve until the 2025 Annual Meeting of Stockholders at the 2022-11-28 meeting.
“Proposal No. 1 – To elect one Class III director for a three-year term to serve until the 2025 Annual Meeting of Stockholders The Company’s stockholders voted for the election of one Class III director, Eric Friedman, to serve until the 2025 Annual Meeting of Stockholders (subject to his respective earlier removal, death or resignation) and until his successor is elected and qualified. The final voting results were as follows: Broker For Withheld Non-Votes Eric Friedman 21,738,259 85,901 1,634,717”
Earnings Releases
INTEGRATED BIOPHARMA INC reported quarter ended September 30, 2022 results: revenue $12.3 million, net income net loss of approximately $35,000 or $0.00 per share, EPS $0.00 per share of common stock.
“Inc. (OTCQX: INBP) (the “Company” or “INBP”) reports its financial results for the quarter ended September 30, 2022. Revenue for the quarter ended September 30, 2022 was $12.3 million compared to $12.8 million for the quarter ended September 30, 2021, a decrease of $0.5 million or approximately 3.1%. The Company had operating income for the quarter ended”
Earnings Releases
INTEGRATED BIOPHARMA INC reported the quarter ended September 30, 2022 results: revenue $12.3 million, net income net loss of approximately $35,000 or $0.00 per share of common stock, EPS $0.00 per share of common stock.
“Integrated BioPharma Reports Results for its Quarter Ended September 30, 2022 HILLSIDE, NEW JERSEY (November 10, 2022) - Integrated BioPharma, Inc. (OTCQX: INBP) (the "Company" or "INBP") reports its financial results for the quarter ended September 30, 2022. Revenue for the quarter ended September 30, 2022 was $12.3 million compared to $12.8 million for the quarter ended September 30, 2021, a decrease of $0.5 million or approximately 3.1%.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.